A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam
about
Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.Physiologically based pharmacokinetic modeling and simulation in pediatric drug developmentDevelopment of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenTreating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.Prediction of drug clearance in children: a review of different methodologies.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects.In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.Pharmacological sedation management in the paediatric intensive care unit.Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Pediatric pharmacology: current efforts and future goals to improve clinical practice.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants.Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspectiveCan Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
P2860
Q27312881-D2C63EF0-6AAE-4D6B-8FD5-2B76A4DC7671Q30838395-611C14DB-20ED-42CE-91DF-B62578D9AF80Q31033069-AA0D2F66-7820-4B79-8EB8-22E575464B16Q34658074-72E00659-FD49-44C9-A684-02FA9BB81C97Q36307045-9C6ED85C-4960-4FF2-8D1E-7A20A3DBD26DQ36322918-D8C6F604-38A7-4A61-A32B-4D0C496F0B54Q36410220-97D12B2F-DA38-4479-B4FE-FEE3C7506C00Q38367747-C53DB013-7B98-4886-9D39-606969B79CBAQ38527434-1A4B8B47-A173-4657-8E72-0E9DA7BFC197Q38639379-7E7F907A-C1CF-4F37-92E9-DB1446D10E3EQ38765921-CCCCE2A3-A5C4-4A02-BCA7-7ACE76BAE55CQ38829350-39B3AF38-A578-44BD-9B77-CF008A1EC5D9Q38841163-C6F2DEB7-CCF8-4C46-80D4-6B97E43E726EQ38959281-2D57C7CB-C5BC-4BE3-A942-54535DCC1DF7Q38985619-E39FC1B8-B5FB-4C58-B3BC-B1FFA8282499Q40670954-DD545342-6B28-4E83-9A08-D08FCC3C8EE1Q41975490-50F97A8F-CBA9-423D-B401-07EADDD6038FQ42320775-FE1B2A58-4FBD-4AF8-815E-EA27FDE33800Q44140105-44BCBA1D-03B8-45B0-B0B0-F6256EDF63B3Q48076685-A1CD6B87-C4F8-44BB-BA89-078715D287BEQ49330212-20835F1A-E39F-4341-BC4F-0C9F6B9F08F8Q55454780-73ADA705-793B-4019-93D3-B686E189699BQ58073610-48D72738-8AF5-443D-94FA-BF58063F8A15Q58739362-DAF187F5-CBCA-4AF2-80D6-AEEA3774EBAA
P2860
A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A workflow example of PBPK mod ...... ent: case study with lorazepam
@en
type
label
A workflow example of PBPK mod ...... ent: case study with lorazepam
@en
prefLabel
A workflow example of PBPK mod ...... ent: case study with lorazepam
@en
P2093
P2860
P1433
P1476
A workflow example of PBPK mod ...... ent: case study with lorazepam
@en
P2093
A N Edginton
A R Maharaj
J S Barrett
P2860
P2888
P304
P356
10.1208/S12248-013-9451-0
P407
P577
2013-01-24T00:00:00Z
P5875
P6179
1045299800